Infectious Disease Threats

This Theme’s Focus

COVID-19 vaccine responses in high-risk populations
Detection of new viral and bacterial threats and clinical risk factors
Characterisation of resistant bacterial and virus variants to inform treatment and vaccine design

Cambridge has a strong track record in microbiology and infectious disease research and is internationally renowned for genomic medicine. This theme aims to combine these two areas of expertise to improve detection, prevention and treatment of existing infectious diseases and help to better prepare for future pandemics.

Translating our research discoveries to the clinic or public health is at the centre of our ethos and our investigators have contributed broadly in the response to the COVID-19 pandemic. This pandemic has highlighted the need for new approaches to understand new and existing infection threats and provide a rapid pathway for new solutions.

For example, we have pioneered the use of genomics to trace outbreaks of COVID in hospitals and now are the centre of COG-UK and SARS-CoV-2 sequencing, allowing our investigators to discover how new variants emerge and their biological properties.

Our research will focus on three key areas, developing new vaccines and treatment strategies for pathogens such as SARS-CoV-2, improving the response of older people to vaccines and bolstering our response to drug-resistant bacteria.

Our approach will involve using genomic surveillance to detect and identify the viruses and other pathogens representing the biggest threats. We will be developing a data and sample repository to help us better understand the epidemiological and clinical nature of infections, and creating a resource for researchers to develop the next generation of solutions.

Theme Leads

Professor Ravindra K Gupta

Professor of Clinical Microbiology at Cambridge University
Email: rkg20@cam.ac.uk

Dr Theodore Gouliouris

Consultant in Microbiology and Infectious Diseases
Email: tg208@cam.ac.uk

Meet our researchers

Here are some of the areas we are researching:

Experimental medicine for COVID-19

New vaccines and treatments for COVID-19 are emerging but a major concern is the rapid emergence of highly-resistant virus strains that could compromise global COVID-19 efforts.

It is important to understand how virus variants emerge so that we can develop strategies to mitigate against new variants and keep vulnerable immunosuppressed patients safe.

We are leading a national trial, PROTECT-V, testing the antibody sotrovimab as a prophylaxis (something which prevents the spread of disease) in more than 1,000 immune-suppressed individuals.

At the same time we are working with people living with immunosuppression across our region, to understand the challenges they and their families face regarding infectious diseases like COVID-19, and involve them in developing study protocols and patient information materials.

Evaluating and boosting COVID-19 vaccine responses in the elderly

The elderly have been largely excluded from major vaccine trials, and existing population-based studies lack age-specific detail – yet this is the group most at risk from COVID-19 and at higher risk of severe disease or death despite vaccination.

To ensure inclusion of appropriate groups, our researchers are undertaking public engagement activities in care homes and day-care centres region-wide, particularly in the more deprived areas such as Corby, where COVID-19 transmission is high, and coastal towns such as Kings Lynn which have high densities of elderly residents.

Alongside this programme, we will take the chance to explore vaccine hesitancy in the families and carers of the elderly,
and in the Traveller communities of Fenland.

Community surveillance for multi-resistant bacteria and viruses

It’s essential to track serious infections if we are to understand how they are spreading and how they might be controlled to avoid illness and death.

Through genomic surveillance (where we look at routinely collected microbiological samples, linked to hospital electronic health records) we can detect new variants and increase our understanding of how they evolve and spread.

We are working closely with hospital laboratories and NIHR BioResource to set up a system to routinely access clinical samples and organisms, on which we can perform genomic surveillance and microbiome analysis to identify key emerging bacterial and viral pathogens.

This will help us develop new therapeutic approaches for emerging pathogens including MDR (multi-drug resistant) bacteria.

Latest News

image with two people - a male and a female

Cambridge researchers honoured at Microbiology Society Annual Awards

April 19, 2023

Congratulations to Professors Sharon Peacock and Ravindra Gupta…

Sneezing - Image from Mojpe from Pixabay

Gone fishing: highly accurate test for common respiratory viruses uses DNA as ‘bait’

January 17, 2023

Research supported by NIHR Cambridge BRC has led to a new test…

Coronavirus. Image by Gerd Altmann from Pixabay.

Blood thinning drug to treat recovery from severe Covid is not effective

November 30, 2022

A Cambridge-led trial has found that a drug used to reduce the risk of blood clots does not help patients recovering from moderate and severe Covid.

Square image with 4 males, 2 above and 2 below

Cambridge researchers listed among world’s most influential researchers

November 21, 2022

Congratulations to our NIHR Cambridge BRC theme leads who have been named in the Clarivate listings of the ‘world’s most influential researchers.’

Patient having their blood test taken at NIHR Cambridge CRF - NIHR Cambridge BRC image

High blood pressure is directly linked to severe COVID-19

November 14, 2022

A new study has shown people with high blood pressure are more likely to be admitted to hospital or die from COVID-19, regardless of other factors such as age, sex, ethnicity or BMI.

Referrals to long COVID clinic fell by 79% following roll-out of the vaccine

October 7, 2022

Referrals to Cambridge’s long COVID clinic fell dramatically in the period August 2021 to June 2022, which researchers say is likely due to the successful rollout of the vaccine.

Cambridge researchers awarded Fellow status

May 11, 2022

Eight Cambridge researchers are elected as Fellows of the Academy of Medical Sciences.

An airfilter machine and Dr Vilas Navapurkar who led the study

Using air filters on hospital wards remove almost all airborne Covid virus

November 17, 2021

A new study has found placing air filtration machines in COVID-19 wards at Addenbrooke's Hospital, removed almost all traces of airborne SARS-CoV-2 virus.

Previous Next

Infectious Disease Threats Case Studies

Patient Having Consultation With Female Doctor In Office

Prioritise vaccine boosters for those with weakened immune systems to prevent emergence of new Covid variants say Cambridge scientists

February 13, 2025

Microscope with samples - NIHR Cambridge BRC image

Could diphtheria become a ‘major global threat’ again as it evolves?

October 16, 2024

In an international study with the UK and India, researchers…

Research scientist in lab: This image was purchased from Abobe Stock with a lifetime usage.

A DNA test that can identify secondary infections in COVID-19 patients

October 16, 2024

Researchers have been able to develop a DNA test to quickly…

How DNA technologies are helping pneumonia patients fight back

October 16, 2024

Many patients who are admitted to intensive care show signs…

Tablets - Image from Cambridge University Health Partners

Using whole genome sequencing to fight common bugs

October 16, 2024

Outbreaks of infections of any type within hospitals and…

Previous Next

Infectious Disease Threats Publications

Resistance mechanisms and population structure of highly drug resistant Klebsiella in Pakistan during the introduction of the carbapenemase NDM-1.

February 20, 2019

Emergence of dominant multidrug-resistant bacterial clades: Lessons from history and whole-genome sequencing.

December 18, 2018

The phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa

November 30, 2018

Genome-Wide Epigenetic and Transcriptomic Characterization of Human-Induced Pluripotent Stem Cell-Derived Intestinal Epithelial Organoids

October 23, 2018

A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid.

October 11, 2018

The NIHR Cambridge BRC is part of the NIHR and hosted by Cambridge University Hospitals NHS Foundation Trust in partnership with the University of Cambridge. We are at the heart of the Cambridge Biomedical Campus, Europe’s largest health research area.

Contact Us

Cambridge Biomedical Research Centre
Box 277
Hills Road
Cambridge
CB2 0QQ

Tel: 01223 348490

Retweet on Twitter NIHR Cambridge Biomedical Research Centre Retweeted

National Institute for Health and Care Research @nihrresearch ·

8 Jun

⏲️One week left to apply for our Researcher Development Programme for Social Care Nurses!

This programme supports social care nurses to develop research skills and explore ideas arising from their day-to-day practice, while remaining in role.

Apply now: https://www.nihr.ac.uk/career-development/researcher-development-programme-social-care-nurses?utm_source=twitter&utm_medium=social&utm_campaign=rdp2026

Reply on Twitter 2063927714407399871 Retweet on Twitter 2063927714407399871 2 Like on Twitter 2063927714407399871 3 Twitter 2063927714407399871

Retweet on Twitter NIHR Cambridge Biomedical Research Centre Retweeted

National Institute for Health and Care Research @nihrresearch ·

8 Jun

📢 Interested in Programme Grants for Applied Research (PGfAR) - October 2026?

There’s still time to join our webinar and find out more about this upcoming funding opportunity.

💻 29 June 2026 | 2.30–4pm

In partnership with @RCPCHtweets, this funding will support ambitious,

Reply on Twitter 2063925134675624105 Retweet on Twitter 2063925134675624105 6 Like on Twitter 2063925134675624105 10 Twitter 2063925134675624105

NIHR Cambridge Biomedical Research Centre @cambridgebrc ·

6 Jun

💡How can patients & the public shape tissue & organ donor research?
📅 16 June
⏰9.20-10.20am
📍Jeffrey Cheah Biomedical Centre @CamBioCampus
🧑‍🤝‍🧑For everyone
🎟️FREE tickets book http://bit.ly/OTDresPPIpanel
😀Attending EoE Showcase? You will need a separate ticket for this talk

Reply on Twitter 2063214319693951382 Retweet on Twitter 2063214319693951382 Like on Twitter 2063214319693951382 Twitter 2063214319693951382

Retweet on Twitter NIHR Cambridge Biomedical Research Centre Retweeted

Research at CPFT @cpft_research ·

5 Jun

📣 Come and spend a day with the Cambridge NeuroWorks team showcasing the latest developments in #neurotech on Monday 15 June!
🔎 Learn about this exciting area of #research & #innovation with @CPFT_NHS to improve healthcare & treatments.
⚡Register ASAP ➡️https://cambridgeneuroworks.org/news-events/neuroworks-2026-scalable-neurotechnology-innovation-translation-and-transformative-treatments

Reply on Twitter 2062875243966771377 Retweet on Twitter 2062875243966771377 3 Like on Twitter 2062875243966771377 7 Twitter 2062875243966771377

Retweet on Twitter NIHR Cambridge Biomedical Research Centre Retweeted

Department of Health and Social Care @dhscgovuk ·

2 Jun

We're expanding research, widening treatment options and tackling inequalities in prostate cancer care.

✅ All eligible Black men will be invited to join a landmark screening trial.

✅ A targeted NHS screening programme will also be rolled out.

More: https://www.gov.uk/government/news/major-expansion-of-research-and-treatment-for-prostate-cancer

Reply on Twitter 2061803520727089292 Retweet on Twitter 2061803520727089292 32 Like on Twitter 2061803520727089292 37 Twitter 2061803520727089292

NIHR Cambridge Biomedical Research Centre @cambridgebrc ·

2 Jun

💡How can patients & public shape tissue & organ donor research?
👍Panel talk with health experts & patients
📅 16 June
⏰9.20-10.20am
📍At @CUH_NHS @CamBioCampus
🧑‍🤝‍🧑For everyone
🎟️FREE tickets book http://bit.ly/OTDresPPIpanel

😀Joining EoE Showcase? You'll need a separate ticket

Reply on Twitter 2061771624823521444 Retweet on Twitter 2061771624823521444 Like on Twitter 2061771624823521444 Twitter 2061771624823521444

View more Tweets

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Infectious Disease Threats

This Theme’s Focus

Theme Leads

Professor Ravindra K Gupta

Dr Theodore Gouliouris

Here are some of the areas we are researching:

Experimental medicine for COVID-19

Evaluating and boosting COVID-19 vaccine responses in the elderly

Community surveillance for multi-resistant bacteria and viruses

Latest News

Infectious Disease Threats Case Studies

Infectious Disease Threats Publications

Contact Us

Useful Links